Clinical trial
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT02386111 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
- Lead sponsor
- Celldex Therapeutics
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 31, 2015
- Completion date
- November 3, 2017
- Enrollment
- 17 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, renal cell, clear-cell metastatic renal cell carcinoma, kidney diseases, kidney neoplasms, neoplasms, neoplasms by histologic type, urogenital neoplasms, urologic diseases, urologic neoplasms